Sedation in ICU

Quick Answer

ICU sedation requires titration to target depth using validated scales (RASS), daily interruption protocols, and agent selection based on patient factors. Light sedation (RASS -2 to 0) improves mortality compared to deep sedation. First-line agents include propofol (short-term), dexmedetomidine (light sedation, delirium prevention), and midazolam (seizures, alcohol withdrawal). Daily sedation interruption (SAT) and spontaneous breathing trials (SBT) reduce ventilator days. Nurse-driven protocols perform as well as strict SAT protocols with better tolerability (SPICE III trial).

CICM Exam Focus: Know RASS scale scoring, pharmacology of propofol/midazolam/dexmedetomidine, indications for daily sedation interruption, contraindications to SAT, evidence from SLEAP and SPICE III trials, and complications of oversedation.

---

Key Points

• Assessment: Richmond Agitation-Sedation Scale (RASS) is validated and widely used; target RASS -2 to 0 for most patients
• Light sedation: Reduces mortality, ventilator days, ICU length of stay compared to deep sedation (RASS -4 to -5)
• Propofol: Rapid onset/offset, first-line for short-term sedation (below 48h); risk of PRIS with prolonged use
• Dexmedetomidine: α2-agonist, arousable sedation, reduces delirium; causes bradycardia and hypotension
• Midazolam: Accumulates in renal/hepatic dysfunction, associated with delirium; use for seizures and alcohol withdrawal
• SAT Protocol: Daily sedation interruption until patient awake or agitated, then restart at 50% dose
• SLEAP Trial: SAT + SBT improved survival and ventilator-free days (PMID: 22016520)
• SPICE III Trial: Dexmedetomidine vs usual care showed no mortality difference; early dexmedetomidine non-inferior (PMID: 30576417)
• DahLIA Trial: Dexmedetomidine vs midazolam for light sedation showed similar ventilator-free days (PMID: 33942969)
• Nurse-driven protocols: As effective as mandatory SAT with better acceptability and fewer adverse events

---

Epidemiology

Prevalence

• Mechanical ventilation: 30-40% of ICU patients require invasive mechanical ventilation
• Sedation use: 70-90% of ventilated patients receive continuous sedation
• Deep sedation prevalence: 40-60% of patients receive RASS -3 to -5 sedation despite guidelines recommending light sedation
• Delirium incidence: 50-80% of mechanically ventilated ICU patients develop delirium; deep sedation is an independent risk factor (PMID: 11445675)

Duration

• Median sedation duration: 3-5 days for general ICU populations
• Prolonged sedation: 20-30% of patients sedated greater than 7 days
• Weaning duration: Average 2-3 days from sedation cessation to extubation

Outcomes

• Mortality: Deep sedation (RASS -4 to -5) associated with increased ICU and hospital mortality (adjusted HR 1.08 per RASS point deeper, PMID: 22016520)
• Ventilator-free days: Light sedation strategies increase ventilator-free days by 2-4 days (PMID: 22016520)
• ICU length of stay: Deep sedation increases ICU LOS by 1-2 days per RASS point deeper (PMID: 18431006)
• Delirium: Deep sedation doubles delirium incidence; benzodiazepines increase delirium risk 2-3 fold (PMID: 19926799)

---

Pathophysiology

Mechanisms of Action

Propofol (GABA-A Agonist)

• Molecular target: Positive allosteric modulator of GABA-A receptor β3 subunit
• CNS effects: Enhances chloride channel opening → neuronal hyperpolarization → global CNS depression
• Subcortical effects: Inhibits thalamocortical circuits, reducing arousal and awareness
• Onset: 30-45 seconds after IV bolus (highly lipophilic, crosses BBB rapidly)
• Offset: 5-10 minutes after short infusion (redistribution to peripheral tissues), 30-60 minutes after prolonged infusion (context-sensitive half-time increases with duration)

Midazolam (GABA-A Agonist - Benzodiazepine)

• Molecular target: Positive allosteric modulator at GABA-A receptor α subunit benzodiazepine binding site
• CNS effects: Enhances GABA-mediated chloride influx → sedation, anxiolysis, amnesia, anticonvulsant
• Active metabolites: 1-hydroxymidazolam (50% activity of parent drug), accumulates in renal impairment
• Onset: 2-5 minutes IV
• Offset: 1-4 hours after single dose, 24-48 hours after prolonged infusion (context-sensitive half-time 200-250 minutes)
• Accumulation: Hepatic metabolism (CYP3A4), renal excretion of metabolites; prolonged sedation in renal/hepatic dysfunction

Dexmedetomidine (α2-Adrenergic Agonist)

• Molecular target: Selective α2A-adrenoceptor agonist (α2:α1 selectivity 1600:1)
• Mechanism: Activates α2A receptors in locus coeruleus (sedation without respiratory depression) and spinal cord dorsal horn (analgesia)
• Unique feature: "Arousable sedation"
• patients can be easily aroused to cooperate, then return to sleep (mimics natural NREM sleep)
• Cardiovascular effects: Initial α1-mediated vasoconstriction (hypertension, reflex bradycardia), then central α2-mediated sympatholysis (hypotension, bradycardia)
• Onset: 5-10 minutes IV (peak effect 15-30 minutes with loading dose)
• Offset: 60-120 minutes (hepatic metabolism, no active metabolites, context-sensitive half-time 40-60 minutes)

---

Sedation Assessment

Richmond Agitation-Sedation Scale (RASS)

The RASS is a validated, reliable, single-item sedation assessment tool with high inter-rater reliability (κ 0.91) (PMID: 12594312).

How to assess:

1. Observe patient (if alert, calm, and attentive = 0; if restless or agitated = +1 to +4)
2. If not alert, state patient's name and say "open your eyes and look at me"
3. If no response to verbal stimulation, physically stimulate by shaking shoulder or rubbing sternum

Target RASS Score

• General ICU patients: RASS -2 to 0 (light sedation, easily arousable)
• Acute respiratory distress syndrome (ARDS): RASS -2 to 0 (unless prone positioning or severe hypoxemia requiring paralysis)
• Post-cardiac arrest: RASS -2 to -1 during targeted temperature management, then -1 to 0
• Traumatic brain injury: RASS -2 to 0 (avoid deep sedation unless refractory intracranial hypertension)
• Status epilepticus: RASS -3 to -5 during titrated pharmacologic coma with EEG monitoring
• Alcohol withdrawal: RASS -1 to 0 (goal is calm, cooperative patient on CIWA-Ar protocol)
• Paralyzed patients: Deep sedation (RASS -4 to -5) mandatory during neuromuscular blockade

Evidence for light sedation: Multiple RCTs and observational studies demonstrate that light sedation (RASS -2 to 0) compared to deep sedation (RASS -4 to -5) reduces:

• ICU mortality (adjusted HR 0.80-0.92 per RASS point lighter, PMID: 22016520)
• Ventilator days (2-4 fewer days, PMID: 18431006)
• ICU length of stay (1-3 fewer days, PMID: 22016520)
• Delirium incidence (40-60% reduction, PMID: 19926799)

---

Sedative Agents

Propofol

Pharmacology

• Formulation: 1% (10 mg/mL) or 2% (20 mg/mL) lipid emulsion (soybean oil, glycerol, egg lecithin)
• Dosing:
  • "Induction: 1-2.5 mg/kg IV bolus (reduce to 0.5-1 mg/kg in elderly, hemodynamically unstable)"
  • "Maintenance: 25-75 mcg/kg/min (1.5-4.5 mg/kg/h) continuous infusion"
  • "Typical ICU range: 0.3-3 mg/kg/h for RASS -2 to 0"
• Onset: 30-45 seconds
• Offset: 5-10 minutes after short infusion, 30-60 minutes after prolonged infusion
• Metabolism: Hepatic conjugation (glucuronidation), extrahepatic metabolism (lungs, kidneys), minimal renal excretion

Advantages

• Rapid titratability: Short context-sensitive half-time allows quick adjustments
• Predictable wake-up: 5-30 minutes after discontinuation (even after days of infusion if no PRIS)
• Anticonvulsant: Useful for status epilepticus (higher doses required, 3-5 mg/kg/h)
• Neuroprotection: Reduces cerebral metabolic rate, may be beneficial in TBI
• Antiemetic: 5-HT3 antagonist properties

Disadvantages

• Hypotension: Vasodilation (inhibits sympathetic vasoconstriction), negative inotropy (dose-dependent)
  • "Incidence: 20-50% of ICU patients, especially with bolus dosing or hypovolemia"
  • "Management: Reduce infusion rate, IV fluid bolus, vasopressors (norepinephrine)"
• Respiratory depression: Dose-dependent apnea, reduced hypoxic/hypercapnic drive
• Propofol infusion syndrome (PRIS): Rare but often fatal (mortality 30-60%)
  • "Incidence: 1-5% with high-dose prolonged infusion"
  • "Risk factors: Dose greater than 4 mg/kg/h, duration greater than 48 hours, young age, critical illness, catecholamine infusions, corticosteroids, inadequate carbohydrate intake"
  • "Pathophysiology: Mitochondrial respiratory chain dysfunction, impaired fatty acid oxidation, rhabdomyolysis"
  • "Clinical features: Metabolic acidosis (anion gap, lactate greater than 5 mmol/L), rhabdomyolysis (CK greater than 5,000 U/L, myoglobinuria), acute kidney injury, cardiac failure (Brugada-like ECG, heart failure), hepatomegaly, lipaemic serum"
  • "Management: Immediate cessation of propofol, switch to alternative sedative, supportive care (RRT for severe acidosis/rhabdomyolysis), consider ECMO for refractory cardiovascular collapse"
• Hypertriglyceridemia: Lipid emulsion delivers 1.1 kcal/mL (10% formulation); risk of pancreatitis if triglycerides greater than 4-5 mmol/L
• Bacterial contamination: Lipid emulsion supports bacterial growth; use aseptic technique, change tubing every 12 hours

Monitoring

• Daily: Triglycerides (if infusion greater than 24 hours), renal function, liver function
• PRIS surveillance (if dose greater than 4 mg/kg/h or duration greater than 48h): Lactate, creatinine kinase, pH/base excess, ECG (Brugada pattern: RBBB + ST elevation V1-V3)

---

Midazolam

Pharmacology

• Formulation: 1 mg/mL or 5 mg/mL aqueous solution
• Dosing:
  • "Bolus: 0.02-0.05 mg/kg IV (1-5 mg typical adult dose)"
  • "Maintenance: 0.02-0.1 mg/kg/h (1-7 mg/h typical adult)"
  • "Alcohol withdrawal: Higher doses often required (up to 10-20 mg/h)"
• Onset: 2-5 minutes IV
• Offset: 1-4 hours after single dose, 24-72 hours after prolonged infusion (context-sensitive half-time increases dramatically with duration)
• Metabolism: Hepatic CYP3A4 → 1-hydroxymidazolam (active metabolite, 50% parent potency) → glucuronide conjugate
• Renal excretion: 70% of metabolites excreted renally; accumulation in renal impairment

Advantages

• Amnesia: Reliably produces anterograde amnesia (useful for unpleasant ICU procedures)
• Anticonvulsant: First-line for status epilepticus unresponsive to benzodiazepines (loading dose 0.2 mg/kg, then 0.05-0.4 mg/kg/h)
• Anxiolysis: Superior anxiolytic effect compared to propofol or dexmedetomidine
• Alcohol withdrawal: Preferred agent for severe alcohol withdrawal (CIWA-Ar protocol) due to cross-tolerance with alcohol at GABA-A receptor
• Hemodynamic stability: Less hypotension than propofol at equivalent sedation depth

Disadvantages

• Accumulation: Prolonged sedation after long-term infusion (context-sensitive half-time greater than 200 minutes after 5+ days)
  • Active metabolite (1-hydroxymidazolam) accumulates in renal impairment
  • Half-life can exceed 24-48 hours after prolonged infusion
• Delirium: Independent risk factor for ICU delirium (OR 1.6-2.0, PMID: 19926799)
  • "Benzodiazepine use associated with transition to delirium (OR 2.0, 95% CI 1.5-2.7, PMID: 19926799)"
• Unpredictable offset: Wake-up time highly variable (30 minutes to 72 hours) after prolonged infusion
• Respiratory depression: Dose-dependent apnea, synergistic with opioids
• Drug interactions: CYP3A4 substrate; metabolism inhibited by macrolides, azole antifungals, protease inhibitors, grapefruit juice

Monitoring

• Daily sedation assessment: RASS score; consider SAT if prolonged infusion (greater than 48h)
• Renal function: Monitor creatinine; expect prolonged offset if CrCl below 50 mL/min
• Hepatic function: Dose reduction if Child-Pugh B or C cirrhosis

---

Dexmedetomidine

Pharmacology

• Formulation: 100 mcg/mL concentrate (dilute to 4 mcg/mL for infusion)
• Dosing:
  • "Loading dose: 0.5-1 mcg/kg IV over 10-20 minutes (optional; omit if bradycardia or hypotension risk)"
  • "Maintenance: 0.2-1.5 mcg/kg/h continuous infusion"
  • "Typical ICU range: 0.2-0.7 mcg/kg/h for RASS -2 to 0"
• Onset: 5-10 minutes IV (peak effect 15-30 minutes with loading dose)
• Offset: 60-120 minutes (context-sensitive half-time 40-60 minutes, independent of infusion duration)
• Metabolism: Hepatic glucuronidation and CYP2A6; no active metabolites; minimal renal excretion

Advantages

• Arousable sedation: Patients can be awakened easily for assessment, then return to sleep (mimics natural NREM sleep via locus coeruleus α2A agonism)
• No respiratory depression: Minimal effect on respiratory drive (useful for non-intubated sedation, post-extubation)
• Analgesia: Opioid-sparing effect (30-50% reduction in morphine equivalents, PMID: 19926799)
• Delirium prevention: Reduces delirium incidence compared to benzodiazepines (RR 0.40-0.60, PMID: 19926799)
• Weaning: Facilitates ventilator weaning and extubation (no respiratory depression, cooperative sedation)
• Predictable offset: Context-sensitive half-time 40-60 minutes regardless of infusion duration

Disadvantages

• Bradycardia: 10-25% incidence (α2-mediated reduction in sympathetic tone)
  • "Risk factors: Baseline HR below 60 bpm, high vagal tone, beta-blockers, heart block"
  • "Management: Reduce infusion rate, atropine 0.5 mg IV, temporary pacing if severe (HR below 40 bpm)"
• Hypotension: 20-35% incidence (central sympatholysis, peripheral α1 agonism causes initial hypertension then rebound hypotension)
  • "Biphasic response: Initial hypertension (10-15 minutes) if loading dose given, then hypotension (30-60 minutes)"
  • "Management: Omit loading dose, reduce infusion rate, IV fluid bolus, vasopressors (norepinephrine preferred)"
• Inadequate deep sedation: Not suitable for RASS -4 to -5 (maximum effect at 1.5 mcg/kg/h is RASS -3)
• Cost: 10-50x more expensive than propofol or midazolam (varies by region)
  • "Cost-effectiveness: May offset by reducing delirium, ventilator days, ICU LOS (PMID: 30576417)"

Monitoring

• Continuous ECG: Monitor for bradycardia (below 60 bpm), heart block
• Blood pressure: Monitor for hypotension (MAP below 65 mmHg) or hypertension (initial loading dose)
• RASS: Assess sedation depth every 4 hours; titrate infusion rate to target

---

Sedation Protocols

Daily Sedation Interruption (SAT)

Definition

Daily cessation of sedative infusions until patient is awake (follows commands or RASS 0 to +1) or agitated (RASS +2 to +4), then restart at 50% of previous dose and titrate to target RASS.

Protocol (SLEAP Trial Protocol, PMID: 22016520)

1. Screen for contraindications (if any present, do NOT perform SAT):

   • Active seizures in past 24 hours
   • Alcohol withdrawal with CIWA-Ar greater than 8 in past 24 hours
   • Neuromuscular blockade (paralysis)
   • Myocardial ischemia in past 24 hours
   • Intracranial hypertension (ICP greater than 20 mmHg)

2. Discontinue sedatives: Turn off propofol, midazolam, dexmedetomidine infusions simultaneously

   • Continue analgesics: Do NOT stop fentanyl, morphine, hydromorphone infusions (pain control maintained)

3. Monitor patient: Assess every 15-30 minutes for:

   • Awakening: Follows commands (squeeze hand, open eyes) OR RASS 0 to +1
   • Agitation: RASS +2 to +4, pulling at tubes, fighting ventilator
   • Distress: Sustained SpO2 below 88%, sustained RR greater than 35/min, acute arrhythmia, myocardial ischemia

4. Restart sedation when:

   • Patient awake (follows commands or RASS 0 to +1), OR
   • Patient agitated (RASS +2 to +4), OR
   • 4 hours elapsed without awakening, OR
   • Distress/safety event occurs

5. Resume infusion: Restart sedative at 50% of previous dose, titrate to target RASS -2 to 0

Evidence: SLEAP Trial (PMID: 22016520)

Design: RCT, 336 mechanically ventilated medical ICU patients, SAT + SBT vs sedation per usual care

Intervention: Daily SAT (turn off sedatives until awake) paired with spontaneous breathing trial (SBT)

Results:

• Mortality: 44% (SAT+SBT) vs 54% (control), p=0.01; 1-year survival HR 0.68 (95% CI 0.50-0.92)
• Ventilator-free days: 14.7 days vs 11.6 days, p=0.02 (absolute difference +3.1 days)
• ICU length of stay: 9.2 days vs 12.9 days, p=0.01 (absolute difference -3.7 days)
• Hospital length of stay: 14.9 days vs 19.2 days, p=0.04 (absolute difference -4.3 days)
• Safety: No difference in self-extubation (10% vs 12%, p=0.50), device removal, or adverse events

Interpretation: Daily SAT paired with SBT improves survival, reduces ventilator days and ICU LOS without increasing adverse events. This is a landmark trial supporting light sedation strategies.

---

Nurse-Driven Sedation Protocols

Definition

Nurses titrate sedative infusions to target RASS score using institutional protocol without mandatory daily interruption. Sedatives adjusted based on RASS assessment every 2-4 hours.

Evidence: SPICE III Trial (PMID: 30576417)

Design: RCT, 4,000 mechanically ventilated ICU patients across 74 ICUs in 5 countries, early dexmedetomidine vs usual care (propofol or midazolam)

Intervention:

• Dexmedetomidine group: Dexmedetomidine 0.2-1.5 mcg/kg/h started within 12 hours of intubation, titrated to RASS -2 to 0 by nurses
• Usual care group: Propofol or midazolam per local protocol, titrated to RASS -2 to 0 by nurses
• No mandatory SAT: Nurses could perform SAT but not required (only 20-30% had SAT)

Results:

• Mortality: 29.1% (dexmedetomidine) vs 29.1% (usual care), p=0.98; adjusted OR 1.00 (95% CI 0.84-1.18)
• Ventilator-free days: 15.4 days vs 15.8 days, p=0.24
• Time to extubation: 3.7 days vs 4.5 days, p=0.21
• Delirium: 63.0% vs 64.0%, p=0.58 (no difference, likely due to nurse-driven protocols achieving light sedation in both groups)
• Adverse events: More bradycardia in dexmedetomidine group (16.0% vs 9.5%, pbelow 0.001), no difference in hypotension

Interpretation: Early dexmedetomidine was non-inferior to usual care (propofol/midazolam) when both groups used nurse-driven protocols targeting light sedation (RASS -2 to 0). This suggests that achieving light sedation target is more important than specific agent choice. Nurse-driven protocols without mandatory SAT may be as effective as SAT protocols if staff are well-trained and target light sedation.

---

Evidence: DahLIA Trial (PMID: 33942969)

Design: RCT, 432 mechanically ventilated ICU patients in Denmark, dexmedetomidine vs midazolam for light sedation (RASS -2 to +1)

Intervention:

• Dexmedetomidine group: 0.2-1.4 mcg/kg/h, titrated to RASS -2 to +1 by nurses
• Midazolam group: 0.5-12 mg/h, titrated to RASS -2 to +1 by nurses
• Protocol: Nurse-driven titration, no mandatory SAT

Results:

• Ventilator-free days (primary outcome): 23.0 days (dexmedetomidine) vs 22.0 days (midazolam), p=0.50; median difference 0 days (95% CI -1 to 1)
• Time to extubation: 2.7 days vs 3.9 days, p=0.24
• ICU length of stay: 5.8 days vs 7.0 days, p=0.29
• Mortality: 27.8% vs 28.2%, p=0.93
• Delirium: 47.5% vs 52.3%, p=0.36 (trend toward less delirium with dexmedetomidine but not significant)
• Adverse events: More bradycardia (11.6% vs 4.6%, p=0.007), less rescue sedation needed (7.4% vs 14.8%, p=0.02)

Interpretation: Dexmedetomidine and midazolam performed similarly for light sedation (RASS -2 to +1) when nurse-driven protocols were used. Both agents can achieve light sedation targets if staff are trained and protocols enforced. Dexmedetomidine may reduce need for rescue sedation but increases bradycardia risk.

---

Protocol Comparison

Clinical implications:

• SAT + SBT: Proven mortality benefit, should be default protocol unless contraindicated
• Nurse-driven protocols: Acceptable alternative if staff trained to target light sedation (RASS -2 to 0); may have better tolerability and acceptability
• Agent choice: Dexmedetomidine vs propofol/midazolam has similar outcomes IF light sedation target achieved; choose based on patient factors (bradycardia risk, cost, duration)

---

Special Populations

Traumatic Brain Injury (TBI)

Sedation goals:

• Target RASS: -2 to 0 (light sedation to allow neurologic assessment)
• Exception: RASS -4 to -5 if refractory intracranial hypertension (ICP greater than 20-25 mmHg despite tier 2 interventions)

Agent selection:

• Propofol: First-line for short-term (below 48h) sedation; reduces cerebral metabolic rate, may lower ICP
  • "Advantages: Rapid titration, predictable wake-up for neuro assessment"
  • "Disadvantages: Hypotension (may reduce CPP), PRIS risk with high-dose prolonged use"
• Midazolam: Second-line if propofol contraindicated (PRIS risk, hypotension)
  • "Disadvantages: Accumulation, unpredictable offset impairs neuro assessment"
• Dexmedetomidine: Use with caution; no clear ICP benefit, risk of hypotension/bradycardia reducing CPP
  • "Consider: For light sedation post-craniotomy when spontaneous breathing desired"

Avoid: Deep sedation (RASS -4 to -5) unless ICP crisis; impairs neurologic assessment and may worsen outcomes

---

Acute Respiratory Distress Syndrome (ARDS)

Sedation goals:

• Target RASS: -2 to 0 (light sedation unless severe hypoxemia or ventilator dyssynchrony)
• Paralysis indication: PaO2/FiO2 below 150 mmHg despite optimal ventilation; target RASS -4 to -5 during paralysis

Agent selection:

• Propofol: First-line for short-term sedation during paralysis (48 hours)
• Midazolam: Alternative if propofol contraindicated; expect prolonged offset
• Dexmedetomidine: Avoid during paralysis (inadequate depth, RASS -3 maximum); consider post-paralysis for weaning

Evidence:

• ACURASYS trial (PMID: 20843245): Cisatracurium paralysis for 48h in severe ARDS (PaO2/FiO2 below 150) improved survival (23.7% vs 33.3%, p=0.05); requires deep sedation (RASS -4 to -5) during paralysis
• ROSE trial (PMID: 31112383): Early paralysis in moderate ARDS (PaO2/FiO2 below 150) showed NO mortality benefit (42.5% vs 42.8%, p=0.93); light sedation without paralysis may be preferred unless severe hypoxemia or dyssynchrony

---

Post-Cardiac Arrest (Targeted Temperature Management)

Sedation goals:

• During TTM (0-24 hours): RASS -4 to -5 (prevent shivering, reduce metabolic demand)
• Post-TTM (24-48 hours): RASS -2 to -1 (allow neurologic assessment)

Agent selection:

• Propofol + fentanyl: First-line for TTM (predictable offset for neuro prognostication at 72h)
• Midazolam + fentanyl: Alternative if propofol contraindicated; expect 24-48h offset after rewarming
• Dexmedetomidine: Avoid during TTM (inadequate depth for shiver suppression); consider post-TTM for light sedation

Shivering management:

• Sedation: Propofol 25-75 mcg/kg/min + fentanyl 25-100 mcg/h
• If shivering persists: Meperidine 25 mg IV bolus (mu-opioid + serotonin reuptake inhibition), then paralysis if refractory

Neurologic prognostication:

• Timing: Minimum 72 hours after ROSC AND 24 hours after cessation of sedation
• Confounding: Propofol offset 6-12h, midazolam offset 24-72h; wait for clinical clearance before prognostication

---

Complications of Oversedation

Delirium

• Incidence: 50-80% of mechanically ventilated ICU patients
• Risk factors: Deep sedation (RASS -4 to -5), benzodiazepine use, prolonged mechanical ventilation, age greater than 65, baseline dementia
• Mechanism: GABA-ergic oversedation disrupts normal sleep architecture, causes cholinergic deficiency, neuroinflammation
• Consequences: Increased mortality (OR 2.0-3.0), prolonged ICU LOS (+5-10 days), long-term cognitive impairment (dementia risk OR 1.4)
• Prevention: Light sedation (RASS -2 to 0), avoid benzodiazepines, early mobilization, sleep hygiene
• Evidence: Benzodiazepine use associated with transition to delirium (OR 2.0, 95% CI 1.5-2.7, PMID: 19926799)

Prolonged Mechanical Ventilation

• Definition: Mechanical ventilation greater than 21 days
• Incidence: 5-15% of ventilated ICU patients; deep sedation increases risk 2-3 fold
• Mechanism: Deep sedation impairs respiratory drive, diaphragm atrophy (ventilator-induced diaphragmatic dysfunction), delayed weaning
• Prevention: Light sedation (RASS -2 to 0), daily SAT + SBT, early mobilization

ICU-Acquired Weakness

• Incidence: 25-50% of mechanically ventilated patients (greater than 7 days)
• Risk factors: Deep sedation, prolonged immobility, corticosteroids, neuromuscular blockade, hyperglycemia
• Mechanism: Critical illness polyneuropathy/myopathy; deep sedation prevents mobilization and worsens disuse atrophy
• Prevention: Light sedation enabling early mobilization (passive ROM, active exercises, ambulation)

Post-Intensive Care Syndrome (PICS)

• Definition: New or worsening impairment in physical, cognitive, or mental health after critical illness
• Incidence: 50-70% of ICU survivors at 1 year
• Components:
  • "Physical: Weakness, fatigue, reduced exercise tolerance (50-60%)"
  • "Cognitive: Memory impairment, executive dysfunction, attention deficits (30-80%)"
  • "Mental health: Depression (30%), PTSD (20-40%), anxiety (30%)"
• Risk factors: Deep sedation, delirium, prolonged mechanical ventilation, sepsis
• Mechanism: Deep sedation → delirium → hippocampal/frontal cortex damage → cognitive impairment
• Prevention: Light sedation (RASS -2 to 0), minimize benzodiazepines, ICU diary, family presence

---

CICM Exam Integration

Written Exam (SAQ) Practice

SAQ 1: Sedation Assessment and Targets

Question: A 55-year-old woman with community-acquired pneumonia has been intubated and ventilated for 72 hours. She is receiving propofol 4 mg/kg/h and fentanyl 100 mcg/h. Her RASS score is -4.

(a) Define the RASS score of -4. (2 marks)

(b) List FOUR adverse consequences of deep sedation (RASS -4 to -5) in mechanically ventilated patients. (4 marks)

(c) Describe your approach to lightening sedation in this patient. (4 marks)

---

Model Answer:

(a) RASS -4 definition (2 marks):

• Deep sedation: No response to verbal stimulation (calling name, "open your eyes") (1 mark)
• Response: Movement or eye opening to physical stimulation only (shoulder shake, sternal rub) (1 mark)

(b) Four adverse consequences of deep sedation (4 marks, 1 mark each):

1. Increased mortality: Deep sedation associated with higher ICU and hospital mortality (adjusted HR 1.08 per RASS point deeper)
2. Prolonged mechanical ventilation: Deep sedation delays ventilator weaning, reduces ventilator-free days by 2-4 days
3. Delirium: Deep sedation is independent risk factor for delirium (OR 1.5-2.0), associated with long-term cognitive impairment
4. ICU-acquired weakness: Deep sedation prevents mobilization, worsens diaphragm atrophy and muscle weakness (incidence 25-50% if ventilated greater than 7 days)

Alternative acceptable answers: Prolonged ICU length of stay, increased risk of VAP, Post-Intensive Care Syndrome (PICS), thromboembolic complications

(c) Approach to lightening sedation (4 marks):

Immediate actions (2 marks):

• Reduce propofol: Decrease infusion rate by 25-50% (from 4 mg/kg/h to 2-3 mg/kg/h initially) OR perform daily sedation interruption (turn off propofol until patient awake or agitated, then restart at 50% dose) (1 mark)
• Continue analgesia: Maintain fentanyl infusion for pain control (do NOT stop opioids during sedation lightening) (0.5 mark)
• Target RASS: Aim for RASS -2 to 0 (light sedation, arousable) (0.5 mark)

Monitoring and titration (2 marks):

• RASS assessment: Assess RASS every 2-4 hours, titrate propofol to target RASS -2 to 0 (0.5 mark)
• Screen for delirium: Use CAM-ICU once RASS ≥-3 (patient arousable to voice) (0.5 mark)
• Spontaneous breathing trial: Pair sedation lightening with daily SBT (T-piece or PSV 5-8 cmH2O for 30 min) to assess readiness for extubation (0.5 mark)
• Safety monitoring: Assess for pain (CPOT/BPS), agitation, ventilator dyssynchrony; increase sedation if unsafe (self-extubation risk, myocardial ischemia) (0.5 mark)

---

SAQ 2: Sedative Pharmacology and Complications

Question: A 68-year-old man has been sedated with propofol 5 mg/kg/h for 96 hours following emergency laparotomy for perforated diverticulitis. He is on norepinephrine 0.2 mcg/kg/min. His lactate has increased from 2 to 8 mmol/L over 24 hours despite source control and antibiotics. His creatinine kinase is 12,000 U/L.

(a) What is the most likely diagnosis? (1 mark)

(b) List THREE other clinical features you would look for to support this diagnosis. (3 marks)

(c) Outline your immediate management. (6 marks)

---

Model Answer:

(a) Most likely diagnosis (1 mark):

• Propofol infusion syndrome (PRIS) (1 mark)

(b) Three other clinical features of PRIS (3 marks, 1 mark each):

1. Metabolic acidosis: Anion gap metabolic acidosis (pH below 7.30, lactate greater than 5 mmol/L, base excess <-5)
2. Cardiac dysfunction: Brugada-like ECG (RBBB + ST elevation in V1-V3), heart failure, arrhythmias, cardiac arrest
3. Hepatomegaly: Fatty infiltration of liver on examination or imaging

Alternative acceptable answers: Acute kidney injury (Cr elevation, myoglobinuria), lipaemic serum (triglycerides greater than 5 mmol/L), hyperkalaemia

(c) Immediate management (6 marks):

Cease propofol (2 marks):

• Stop propofol immediately: Discontinue propofol infusion (PRIS mortality 30-60%; propofol cessation is definitive treatment) (1 mark)
• Switch sedative: Start alternative sedation (midazolam 2-5 mg/h OR dexmedetomidine 0.2-0.7 mcg/kg/h) to maintain RASS target (1 mark)

Supportive care (2 marks):

• Correct acidosis: Sodium bicarbonate if pH below 7.20 (consider renal replacement therapy if severe, persistent acidosis) (0.5 mark)
• Manage rhabdomyolysis: Aggressive IV fluid resuscitation (target urine output greater than 2 mL/kg/h), monitor urine for myoglobin, consider RRT if oliguric AKI or severe hyperkalaemia (0.5 mark)
• Cardiovascular support: Escalate vasopressors/inotropes as needed (norepinephrine, add vasopressin or epinephrine if refractory hypotension); consider ECMO if refractory cardiovascular collapse (0.5 mark)
• Monitor: Serial lactate, CK, renal function, ECG (Brugada pattern, arrhythmias), echocardiography (LV function) (0.5 mark)

Prevent recurrence (1 mark):

• Avoid propofol: Do NOT restart propofol in this patient; use alternative sedatives (midazolam, dexmedetomidine) for remainder of ICU stay (0.5 mark)
• Monitor triglycerides: If using lipid emulsion sedatives (propofol) in future patients, monitor triglycerides daily and keep dose below 4 mg/kg/h for below 48 hours (0.5 mark)

Multidisciplinary (1 mark):

• Intensivist review: Senior review for PRIS diagnosis confirmation and management plan (0.5 mark)
• Pharmacy: Alert pharmacy to propofol allergy/contraindication in medical record (0.5 mark)

---

Viva Voce Scenarios

Viva 1: Daily Sedation Interruption Protocol

Scenario: You are the ICU consultant. A 60-year-old woman has been ventilated for 5 days with severe community-acquired pneumonia (ARDS, PaO2/FiO2 180). She is receiving midazolam 4 mg/h and fentanyl 100 mcg/h. The nurse asks if she should perform a daily sedation interruption today.

Stem questions:

1. What is a daily sedation interruption (SAT)? What is the evidence supporting it?
2. What are the contraindications to SAT in this patient?
3. How would you perform SAT in this patient?
4. What are the potential adverse events of SAT, and how would you monitor for them?

---

Model Answer:

1. Daily sedation interruption (SAT) definition and evidence (25% of marks):

• Definition: Daily cessation of sedative infusions until patient awake (follows commands, RASS 0 to +1) or agitated (RASS +2 to +4), then restart at 50% of previous dose and titrate to target
• Evidence: SLEAP trial (Girard et al., Lancet 2008, PMID: 22016520)
  • "Design: RCT of 336 mechanically ventilated patients, SAT + SBT vs usual care"
  • "Results: SAT + SBT improved 1-year survival (HR 0.68, p=0.01), increased ventilator-free days (+3.1 days, p=0.02), reduced ICU LOS (-3.7 days, p=0.01)"
  • "Safety: No increase in self-extubation (10% vs 12%) or device removal"
• Mechanism: Prevents sedative accumulation, reduces deep sedation, facilitates earlier ventilator weaning

2. Contraindications to SAT (25% of marks):

Screen for absolute contraindications (if any present, do NOT perform SAT):

• Active seizures in past 24 hours (risk of seizure recurrence if benzodiazepine stopped)
• Alcohol withdrawal with CIWA-Ar greater than 8 in past 24 hours (risk of withdrawal seizures)
• Neuromuscular blockade (patient paralyzed; cannot assess awakening)
• Myocardial ischemia in past 24 hours (catecholamine surge during SAT may worsen ischemia)
• Intracranial hypertension (ICP greater than 20 mmHg; awakening may increase ICP)

This patient: No absolute contraindications listed; SAT is appropriate if no history of seizures, alcohol withdrawal, ischemia, or ICP issues.

3. How to perform SAT (30% of marks):

Protocol:

1. Turn off sedatives: Discontinue midazolam infusion (4 mg/h → 0)
2. Continue analgesics: Maintain fentanyl 100 mcg/h (do NOT stop opioids; pain control essential)
3. Monitor every 15-30 min for:
   • Awakening: Follows commands (squeeze hand, open eyes) OR RASS 0 to +1
   • Agitation: RASS +2 to +4 (pulling at ETT, fighting ventilator)
   • Distress: SpO2 below 88% sustained, RR greater than 35/min sustained, acute arrhythmia, ischemia
4. Restart midazolam when:
   • Patient awake (RASS 0 to +1) OR
   • Patient agitated (RASS +2 to +4) OR
   • 4 hours elapsed without awakening OR
   • Distress/safety event
5. Resume at 50% dose: Restart midazolam at 2 mg/h (50% of 4 mg/h), titrate to RASS -2 to 0
6. Pair with SBT: If patient awakens and no contraindications, perform spontaneous breathing trial (T-piece or PSV 5-8 cmH2O for 30 min) to assess extubation readiness

4. Adverse events and monitoring (20% of marks):

Potential adverse events:

• Self-extubation: 10% incidence in SLEAP trial (not significantly different from control)
• Device removal: Pulling out central lines, arterial lines, urinary catheters
• Agitation/delirium: May occur during awakening (RASS +2 to +4)
• Ventilator dyssynchrony: Fighting ventilator during awakening (risk of barotrauma, desaturation)
• Myocardial ischemia: Catecholamine surge during awakening (rare, below 1%)

Monitoring:

• Nurse at bedside: Continuous monitoring during SAT (every 15-30 min assessment)
• Vital signs: HR, BP, SpO2, RR (watch for tachycardia, hypertension, desaturation, tachypnea)
• RASS: Assess every 15-30 min; restart sedation if RASS +2 to +4 or distress
• Safety restraints: Ensure soft wrist restraints in place (prevent tube/line removal)
• ECG monitoring: Watch for arrhythmias or ischemia (ST changes)

---

Examiner guidance:

• Pass: Defines SAT correctly, cites SLEAP trial, screens for contraindications, describes SAT protocol (turn off sedatives, continue opioids, monitor for awakening), identifies adverse events (self-extubation, agitation), appropriate monitoring
• Fail: Cannot define SAT, unaware of contraindications (eg. performs SAT during active seizures or alcohol withdrawal), unsafe protocol (stops opioids, no monitoring plan), dismisses adverse event risks

---

Viva 2: Sedative Selection and Pharmacology

Scenario: You are consulted by the ED about a 45-year-old man intubated for severe pneumonia. The ED doctor asks which sedative agent you recommend for the next 24-48 hours in ICU.

Stem questions:

1. What sedative agents are available, and what are their mechanisms of action?
2. Compare propofol and dexmedetomidine for this patient. What are the advantages and disadvantages of each?
3. The team chooses propofol. After 3 days, his propofol dose is 5 mg/kg/h and he is on norepinephrine 0.3 mcg/kg/min. What complication are you concerned about, and how would you monitor for it?
4. What is propofol infusion syndrome (PRIS)? How would you manage it?

---

Model Answer:

1. Sedative agents and mechanisms (20% of marks):

Available ICU sedatives:

2. Propofol vs dexmedetomidine comparison (30% of marks):

Propofol advantages:

• Rapid titratability: Short context-sensitive half-time (10-40 min) allows quick adjustments
• Predictable offset: Awakens 5-30 min after discontinuation (useful for daily sedation interruption)
• Deep sedation capable: Can achieve RASS -4 to -5 if needed (eg. refractory hypoxemia, ventilator dyssynchrony)
• Anticonvulsant: Useful if seizure risk

Propofol disadvantages:

• Hypotension: Vasodilation and negative inotropy (20-50% incidence); may worsen shock requiring higher vasopressor doses
• PRIS risk: Rare but fatal (1-5%) with prolonged high-dose infusion (greater than 4 mg/kg/h for greater than 48h)
• No analgesia: Requires co-administration of opioids for pain control
• Respiratory depression: Dose-dependent apnea

Dexmedetomidine advantages:

• Arousable sedation: Patients easily awakened for assessment, then return to sleep (mimics natural sleep)
• No respiratory depression: Safe for non-intubated or post-extubation sedation
• Analgesia: Opioid-sparing effect (30-50% reduction in morphine equivalents)
• Delirium prevention: Reduces delirium vs benzodiazepines (RR 0.40-0.60)
• Predictable offset: Context-sensitive half-time 40-60 min regardless of infusion duration

Dexmedetomidine disadvantages:

• Bradycardia: 10-25% incidence (HR below 60 bpm); risk of heart block
• Hypotension: 20-35% incidence (may worsen shock, require higher vasopressor doses)
• Inadequate deep sedation: Cannot achieve RASS -4 to -5 (maximum effect RASS -3 at 1.5 mcg/kg/h)
• Cost: 10-50x more expensive than propofol

Recommendation for this patient (severe pneumonia, likely 24-48h ventilation):

• Propofol 25-75 mcg/kg/min (1.5-4.5 mg/kg/h) + fentanyl 25-100 mcg/h
  • "Rationale: Short-term sedation (below 48h), rapid offset for daily sedation interruption and extubation readiness assessment, cost-effective"
  • "Monitor: Blood pressure (may need vasopressors), triglycerides if greater than 48h, RASS target -2 to 0"

3. Complication concern after 3 days of high-dose propofol (20% of marks):

Concern: Propofol infusion syndrome (PRIS)

Risk factors present:

• High dose: 5 mg/kg/h (greater than 4 mg/kg/h threshold)
• Prolonged duration: 3 days (greater than 48h threshold)
• Catecholamine infusion: Norepinephrine 0.3 mcg/kg/min (increases PRIS risk)

Monitoring for PRIS:

• Daily labs: Lactate (rising trend, greater than 5 mmol/L concerning), creatinine kinase (rhabdomyolysis, greater than 5,000 U/L concerning), creatinine (AKI), triglycerides (greater than 4-5 mmol/L), pH/base excess (metabolic acidosis)
• ECG: Brugada pattern (RBBB + ST elevation V1-V3), arrhythmias
• Clinical: Hepatomegaly (fatty liver), lipaemic serum, unexplained cardiovascular collapse

Action: Consider switching to alternative sedative (midazolam or dexmedetomidine) if propofol dose greater than 4 mg/kg/h required for greater than 48-72h

4. PRIS definition and management (30% of marks):

Propofol infusion syndrome (PRIS):

• Definition: Rare (1-5% incidence) but often fatal (mortality 30-60%) complication of prolonged high-dose propofol
• Pathophysiology: Mitochondrial respiratory chain dysfunction → impaired fatty acid oxidation → rhabdomyolysis, cardiac failure, metabolic acidosis
• Clinical features:
  • "Metabolic acidosis: Anion gap, lactate greater than 5 mmol/L, base excess <-10"
  • "Rhabdomyolysis: CK greater than 5,000 U/L, myoglobinuria, AKI"
  • "Cardiac dysfunction: Brugada-like ECG (RBBB + ST elevation V1-V3), heart failure, arrhythmias, cardiac arrest"
  • "Hepatomegaly: Fatty infiltration"
  • "Lipaemic serum: Triglycerides greater than 5 mmol/L (lipid emulsion accumulation)"

Management:

1. Stop propofol immediately: Definitive treatment; switch to alternative sedative (midazolam 2-5 mg/h OR dexmedetomidine 0.2-0.7 mcg/kg/h)
2. Supportive care:
   • Acidosis: Sodium bicarbonate if pH below 7.20; consider RRT for severe, persistent acidosis
   • Rhabdomyolysis: Aggressive IV fluid resuscitation (target UO greater than 2 mL/kg/h), monitor for myoglobin, RRT if oliguric AKI or hyperkalaemia
   • Cardiovascular: Escalate vasopressors/inotropes (norepinephrine, epinephrine); consider ECMO if refractory cardiovascular collapse
3. Monitoring: Serial lactate, CK, renal function, ECG, echocardiography (LV function)
4. Prevention: Avoid propofol doses greater than 4 mg/kg/h for greater than 48h; monitor triglycerides daily if prolonged infusion

---

Examiner guidance:

• Pass: Describes mechanisms of propofol/dexmedetomidine, compares advantages/disadvantages correctly, identifies PRIS as complication of high-dose prolonged propofol (risk factors: dose greater than 4 mg/kg/h, duration greater than 48h, catecholamines), lists clinical features (acidosis, rhabdomyolysis, cardiac dysfunction), outlines management (stop propofol, supportive care, RRT, ECMO)
• Fail: Cannot describe mechanisms, unaware of PRIS or confuses with other complications (eg. infection), unsafe management (continues propofol despite PRIS diagnosis), does not mention stopping propofol as definitive treatment

---

Summary

ICU sedation requires a patient-centered approach balancing comfort, safety, and liberation from mechanical ventilation. Light sedation (RASS -2 to 0) improves survival, reduces ventilator days, and minimizes delirium compared to deep sedation. Daily sedation interruption protocols (SAT + SBT) are evidence-based strategies that improve outcomes, though nurse-driven protocols targeting light sedation may be equally effective with better acceptability.

Propofol is first-line for short-term sedation due to rapid titratability and predictable offset, but carries risks of hypotension and propofol infusion syndrome with prolonged high-dose use. Dexmedetomidine offers arousable sedation without respiratory depression and reduces delirium, but causes bradycardia and hypotension and is inadequate for deep sedation. Midazolam is reserved for specific indications (seizures, alcohol withdrawal) due to accumulation and delirium risk.

Key CICM exam points:

• RASS scale: Know scoring (-5 to +4) and target RASS -2 to 0 for most patients
• Propofol: GABA-A agonist, rapid offset, PRIS risk (dose greater than 4 mg/kg/h for greater than 48h)
• Dexmedetomidine: α2-agonist, arousable sedation, bradycardia/hypotension, delirium prevention
• Midazolam: GABA-A agonist, accumulation in renal/hepatic dysfunction, delirium risk
• SAT protocol: Turn off sedatives daily until awake or agitated, restart at 50% dose
• SLEAP trial: SAT + SBT improved survival (HR 0.68), ventilator-free days (+3.1 days)
• SPICE III trial: Dexmedetomidine vs usual care showed no mortality difference (nurse-driven protocols effective)
• Complications: Deep sedation increases mortality, delirium, ICU-acquired weakness, PICS

---

References

1. Sessler CN, Gosnell MS, Grap MJ, et al. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med. 2002;166(10):1338-1344. PMID: 12594312

2. Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet. 2008;371(9607):126-134. PMID: 22016520

3. Shehabi Y, Howe BD, Bellomo R, et al. Early sedation with dexmedetomidine in critically ill patients (SPICE III): a multicentre randomised controlled trial. Lancet Respir Med. 2019;7(3):267-276. PMID: 30576417

4. Andersen-Ranberg NC, Poulsen LM, Perner A, et al. Dexmedetomidine versus midazolam for sedation of patients with acute respiratory distress syndrome (DahLIA): a randomised trial. Intensive Care Med. 2021;47(3):355-365. PMID: 33942969

5. Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med. 2000;342(20):1471-1477. PMID: 10816184

6. Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004;291(14):1753-1762. PMID: 11445675

7. Pandharipande P, Shintani A, Peterson J, et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology. 2006;104(1):21-26. PMID: 19926799

8. Shehabi Y, Bellomo R, Reade MC, et al. Early goal-directed sedation versus standard sedation in mechanically ventilated critically ill patients: a pilot study. Crit Care Med. 2013;41(8):1983-1991. PMID: 23863230

9. Treggiari MM, Romand JA, Yanez ND, et al. Randomized trial of light versus deep sedation on mental health after critical illness. Crit Care Med. 2009;37(9):2527-2534. PMID: 19623052

10. Strøm T, Martinussen T, Toft P. A protocol of no sedation for critically ill patients receiving mechanical ventilation: a randomised trial. Lancet. 2010;375(9713):475-480. PMID: 20116842

11. Cremer OL, Moons KG, Bouman EA, et al. Long-term propofol infusion and cardiac failure in adult head-injured patients. Lancet. 2001;357(9250):117-118. PMID: 11197397

12. Bray RJ. Propofol infusion syndrome in children. Paediatr Anaesth. 1998;8(6):491-499. PMID: 9836214

13. Fodale V, La Monaca E. Propofol infusion syndrome: an overview of a perplexing disease. Drug Saf. 2008;31(4):293-303. PMID: 18366240

14. Devlin JW, Skrobik Y, Gélinas C, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med. 2018;46(9):e825-e873. PMID: 30113379

15. Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41(1):263-306. PMID: 23269131

16. Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009;301(5):489-499. PMID: 19188334

17. Jakob SM, Ruokonen E, Grounds RM, et al. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA. 2012;307(11):1151-1160. PMID: 22436955

18. Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363(12):1107-1116. PMID: 20843245

19. National Heart, Lung, and Blood Institute PETAL Clinical Trials Network. Early neuromuscular blockade in the acute respiratory distress syndrome (ROSE). N Engl J Med. 2019;380(21):1997-2008. PMID: 31112383

20. Moss M, Huang DT, Brower RG, et al. Early neuromuscular blockade in the acute respiratory distress syndrome. N Engl J Med. 2019;380(21):1997-2008. PMID: 31112383

21. Tanaka LM, Azevedo LC, Park M, et al. Early sedation and clinical outcomes of mechanically ventilated patients: a prospective multicenter cohort study. Crit Care. 2014;18(4):R156. PMID: 25047960

22. Stephens RJ, Dettmer MR, Roberts BW, et al. Practice patterns and outcomes associated with early sedation depth in mechanically ventilated patients: a systematic review and meta-analysis. Crit Care Med. 2018;46(3):471-479. PMID: 29227368

23. Shehabi Y, Chan L, Kadiman S, et al. Sedation depth and long-term mortality in mechanically ventilated critically ill adults: a prospective longitudinal multicentre cohort study. Intensive Care Med. 2013;39(5):910-918. PMID: 23344834

24. Balzer F, Weiß B, Kumpf O, et al. Early deep sedation is associated with decreased in-hospital and two-year follow-up survival. Crit Care. 2015;19:197. PMID: 25928417

25. Brook AD, Ahrens TS, Schaiff R, et al. Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. Crit Care Med. 1999;27(12):2609-2615. PMID: 10628598

26. De Wit M, Gennings C, Jenvey WI, Epstein SK. Randomized trial comparing daily interruption of sedation and nursing-implemented sedation algorithm in medical intensive care unit patients. Crit Care. 2008;12(3):R70. PMID: 18498644

27. Mehta S, Burry L, Cook D, et al. Daily sedation interruption in mechanically ventilated critically ill patients cared for with a sedation protocol: a randomized controlled trial. JAMA. 2012;308(19):1985-1992. PMID: 23180503

28. Kollef MH, Levy NT, Ahrens TS, et al. The use of continuous i.v. sedation is associated with prolongation of mechanical ventilation. Chest. 1998;114(2):541-548. PMID: 9726743

29. Carson SS, Kress JP, Rodgers JE, et al. A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients. Crit Care Med. 2006;34(5):1326-1332. PMID: 16540958

30. Chanques G, Jaber S, Barbotte E, et al. Impact of systematic evaluation of pain and agitation in an intensive care unit. Crit Care Med. 2006;34(6):1691-1699. PMID: 16625136

31. Payen JF, Chanques G, Mantz J, et al. Current practices in sedation and analgesia for mechanically ventilated critically ill patients: a prospective multicenter patient-based study. Anesthesiology. 2007;106(4):687-695. PMID: 17413906

32. Bugedo G, Tobar E, Aguirre M, et al. The implementation of an analgesia-based sedation protocol reduced deep sedation and proved to be safe and feasible in patients on mechanical ventilation. Rev Bras Ter Intensiva. 2013;25(3):188-196. PMID: 24213080

33. Arroliga A, Frutos-Vivar F, Hall J, et al. Use of sedatives and neuromuscular blockers in a cohort of patients receiving mechanical ventilation. Chest. 2005;128(2):496-506. PMID: 18431006

34. Schweickert WD, Pohlman MC, Pohlman AS, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet. 2009;373(9678):1874-1882. PMID: 19446324

35. Needham DM, Davidson J, Cohen H, et al. Improving long-term outcomes after discharge from intensive care unit: report from a stakeholders' conference. Crit Care Med. 2012;40(2):502-509. PMID: 21946660

36. Jackson JC, Pandharipande PP, Girard TD, et al. Depression, post-traumatic stress disorder, and functional disability in survivors of critical illness in the BRAIN-ICU study: a longitudinal cohort study. Lancet Respir Med. 2014;2(5):369-379. PMID: 24815803

37. Hopkins RO, Weaver LK, Collingridge D, et al. Two-year cognitive, emotional, and quality-of-life outcomes in acute respiratory distress syndrome. Am J Respir Crit Care Med. 2005;171(4):340-347. PMID: 15542793

38. Pandharipande PP, Girard TD, Jackson JC, et al. Long-term cognitive impairment after critical illness. N Engl J Med. 2013;369(14):1306-1316. PMID: 24088092

---

Document Metadata:

• Lines: ~1,520
• Citations: 38 PubMed references
• Target Audience: CICM Second Part candidates
• Content Depth: Comprehensive coverage of sedation assessment (RASS), pharmacology (propofol, midazolam, dexmedetomidine), protocols (SAT, nurse-driven), evidence (SLEAP, SPICE III, DahLIA trials), complications (PRIS, delirium), and exam-focused SAQs and vivas
• Last Updated: 2025-01-24